Drug Combination Approved in Melanoma; Dana-Farber Challenges BMS Patent Rights

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A combination of two Bristol-Myers Squibb immuno-oncology agents—Opdivo (nivolumab) and Yervoy (ipilimumab)—received an accelerated approval for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Matthew Bin Han Ong
Senior Editor

YOU MAY BE INTERESTED IN

Matthew Bin Han Ong
Senior Editor

Login